Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?

References

• Global Initiative for Chronic Obstructive Lung Disease [Internet]. Global initiative for chronic obstructive lung disease - GOLD. [cited 2020 Sept 29]. Available from: https://goldcopd.org/
   Google Scholar
• Chronic obstructive pulmonary disease (COPD). [cited 2020 Sept 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
   Google Scholar
• WHO | COPD: Definition. WHO; [cited 2020 Sept 29]. Available from: https://www.who.int/respiratory/copd/definition/en/
   Google Scholar
• van Boven JFM, van de Hei SJ, Sadatsafavi M. Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists. Eur Respir J. 2019;53(3):1801816.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; 2015.
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17:5–14.
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis. 2008;3:71–88.
   PubMedGoogle Scholar
• Rutten-van Mölken MPMH, Goossens LMA. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30:271–302.
   PubMed Web of Science ®Google Scholar
• van der Schans S, Goossens LMA, Boland MRS, et al. Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: methodological considerations and recommendations. Pharmacoeconomics. 2017;35:43–63.
   PubMed Web of Science ®Google Scholar
• Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240–245.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049-f1049.
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9:53–61.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Rayyan QCRI, The systematic reviews web app. [cited 2020 Jul 15]. Available from: https://rayyan.qcri.org/welcome
   Google Scholar
• Fens T, van der Pol S, Kocks JWH, et al. Economic impact of reducing inappropriate inhaled corticosteroids use in patients with chronic obstructive pulmonary disease: ISPOR’s guidance on budget impact in practice. Value Health. 2019;22:1092–1101.
   PubMed Web of Science ®Google Scholar
• Carvalho N, Jit M, Cox S, et al. Capturing budget impact considerations within economic evaluations: a systematic review of economic evaluations of rotavirus vaccine in low- and middle-income countries and a proposed assessment framework. Pharmacoeconomics. 2018;36:79–90.
   PubMed Web of Science ®Google Scholar
• Loze PM, Nasciben LB, Sartori AMC, et al. Vaccines are different: a systematic review of budget impact analyses of vaccines. Vaccine. 2017;35:2781–2793.
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Corro Ramos I, Baldwin M, et al. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. Int J Chron Obstruct Pulmon Dis. 2019;14:447–456.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Bloudek L, Marvel J, et al. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. Int J Chron Obstruct Pulmon Dis. 2018;13:3867–3877.
   PubMed Web of Science ®Google Scholar
• Driessen M, Shah D, Risebrough N, et al. Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respir Med. 2018;145:130–137.
   PubMed Web of Science ®Google Scholar
• Driessen MT, Whalen J, Seewoodharry Buguth B, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62. 5/25mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish national healthcare system perspective. Respir Res. 2018;19. DOI:10.1186/s12931-018-0916-7.
   Web of Science ®Google Scholar
• Skoupa J, Kasak V, Klimes J, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in patients with COPD—a cost-effectiveness analysis in the Czech Republic. Value Health Reg Issues. 2018;16:112–118.
   PubMedGoogle Scholar
• Shah D, Driessen M, Risebrough N, et al. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Eff Resour Alloc. 2018;16:16.
   PubMed Web of Science ®Google Scholar
• Chan M-C, Tan EC-H, Yang M-C. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2018;1079–1088. DOI:10.2147/COPD.S159103
   PubMed Web of Science ®Google Scholar
• Bjermer L, van Boven JFM, Costa-Scharplatz M, et al. Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respir Res. 2017;18:206.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Patel JG, Coleman A, et al. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008.
   PubMed Web of Science ®Google Scholar
• Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016;8:667–674.
   PubMedGoogle Scholar
• van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11:2191–2201.
   PubMed Web of Science ®Google Scholar
• Ramos M, Haughney J, Henry N, et al. Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res. 2016;8:445–456.
   PubMed Web of Science ®Google Scholar
• Reza Maleki-Yazdi M, Molimard M, Keininger DL, et al. Cost effectiveness of the long-acting β2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and Portugal. Appl Health Econ Health Policy. 2016;14:579–594.
   PubMed Web of Science ®Google Scholar
• Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10:391–401.
   PubMed Web of Science ®Google Scholar
• Eklund O, Afzal F, Borgström F, et al. Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. Clinicoecon Outcomes Res. 2016;8:243–252.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Gáldiz JB, Huerta A, et al. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016;11:123–132.
   PubMed Web of Science ®Google Scholar
• Schroeder M, Shah D, Risebrough N, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective. Respirat Med. 2019;1:100008.
   Google Scholar
• Tee A, Chow WL, Burke C, et al. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore. Singapore Med J. 2018;59:383–389.
   PubMed Web of Science ®Google Scholar
• Capel M, Mareque M, Álvarez CJ, et al. Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig. 2018;38:611–620.
   PubMed Web of Science ®Google Scholar
• Darbà J, Ramírez G, García-Rivero JL, et al. Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain. Clinicoecon Outcomes Res. 2017;9:127–137.
   PubMed Web of Science ®Google Scholar
• Vallejo-Aparicio LA, Peces-Barba G, Gil A, et al. Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS. Clinicoecon Outcomes Res. 2018;Volume 10:501–510.
   Web of Science ®Google Scholar
• Aiello A, Ritrovato D, Pitotti C. Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study. Glob Reg Health Technol Assess. 2018:2284240318804808.
   Web of Science ®Google Scholar
• Iannazzo S, Distante C, Corsico AG. Costs of Tiotropium Bromide Delivered via the Respimat® Inhaler in COPD Patients in Italy. Glob Reg Health Technol Assess. 2016;3:GRHTA.5000220. .
   Web of Science ®Google Scholar
• Lewis A, Torvinen S, Dekhuijzen PNR, et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: the potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017;129:179–188.
   PubMed Web of Science ®Google Scholar
• Kiff C, Ruiz S, Varol N, et al. Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK. Int J Chron Obstruct Pulmon Dis. 2018;13:2707–2720.
   PubMed Web of Science ®Google Scholar
• Зырянов СК, Дьяков ИН. Фармакоэкономическая оценка двойной бронходилатационной терапии у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2018:61–68. Available from https://journal.pulmonology.ru/pulm/article/view/962
   Google Scholar
• Trudo F, Kern DM, Davis JR, et al. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015;10:2055–2066.
   PubMed Web of Science ®Google Scholar
• Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14:97–101.
   Google Scholar
• Dekhuijzen R, Lavorini F, Usmani OS, et al. Addressing the impact and unmet needs of nonadherence in asthma and chronic obstructive pulmonary disease: where do we go from here? J Allergy Clin Immunol. 2018;6:785–793.
   Web of Science ®Google Scholar
• Cushen B, Sulaiman I, Greene G, et al. The clinical impact of different adherence behaviors in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197:1630–1633.
   PubMed Web of Science ®Google Scholar
• van Boven JFM, Ryan D, Eakin MN, et al. Enhancing respiratory medication adherence: the role of health care professionals and cost-effectiveness considerations. J Allergy Clin Immunol Pract. 2016;4:835–846.
   PubMed Web of Science ®Google Scholar
• van Boven JFM, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res. 2014;15:66.
   PubMed Web of Science ®Google Scholar
• van Boven JFM, Cushen B, Sulaiman I, et al. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. NPJ Prim Care Respir Med. 2018;28:1–3.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Puxeddu E, et al. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117–123.
   PubMed Web of Science ®Google Scholar
• Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22:454–475.
   PubMedGoogle Scholar
• Müllerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–1178.
   PubMed Web of Science ®Google Scholar
• Dimitrova M, Kamusheva M, Tachkov K, et al. Cardiovascular co-morbidity in patients with COPD in Bulgaria. Biotechnol Biotechnol Equip. 2020;34:918–924.
   Web of Science ®Google Scholar
• Chetty U, McLean G, Morrison D, et al. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67:e321–e328.
   PubMed Web of Science ®Google Scholar
• Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20:1160–1171.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Boyd C, Boschetto P, et al. How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc. 2012;9:274–281.
   PubMedGoogle Scholar
• Corsonello A, Antonelli Incalzi R, Pistelli R, et al. Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2011;17(Suppl 1):S21–28.
   PubMedGoogle Scholar
• EMA. Authorisation of medicines [Internet]. European Medicines Agency; 2018. [cited 2020 Sept 20]. Available from: https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines
   Google Scholar
• Rogliani P, Matera MG, Ora J, et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469–3485.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Puxeddu E, et al. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opin Drug Saf. 2018;17:509–517.
   PubMed Web of Science ®Google Scholar
• van Boven JFM, de Jong-van den Berg LTW, Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf. 2013;36:231–236.
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22:92–100.
   PubMedGoogle Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219–229.
   PubMed Web of Science ®Google Scholar
• Tabyshova A, Hurst JR, Soriano JB, et al. Gaps in COPD guidelines of low- and middle income countries: a systematic scoping review. Chest. 2020. DOI:10.1016/j.chest.2020.09.260.
   PubMed Web of Science ®Google Scholar